AbbVie Highlights Strong Solid Tumor Pipeline at ASCO 2024 with New ADC Data

AbbVie has revealed new safety and efficacy data from its advanced antibody-drug conjugate (ADC) platform, showcasing promising results for patients with metastatic colorectal cancer (CRC), small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors, and high-grade neuroendocrine neoplasms (NENs). The data will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

ABBV-400, a next-generation c-Met directed ADC, has shown encouraging outcomes in a Phase 1 study. The study involved 122 heavily pre-treated CRC patients, with an objective response rate (ORR) of 18% and 24% at doses of 2.4 and 3.0 mg/kg, respectively. In patients with higher c-Met expression, the ORR increased to over 35%. Common adverse events included anemia, neutropenia, and febrile neutropenia. ABBV-400 is also under evaluation in further studies for advanced solid tumors and second-line metastatic CRC.

ABBV-706, another potential best-in-class ADC targeting SEZ6, demonstrated a 43.8% ORR in 48 efficacy-evaluable patients, including a 60.9% ORR in the SCLC subgroup. The study noted adverse events such as neutropenia, anemia, and leukopenia. ABBV-706 is being assessed as a monotherapy and in combination with other treatments for various advanced solid tumors.

The LUMINOSITY trial's primary analysis on Telisotuzumab vedotin (Teliso-V), targeting c-Met in advanced non-small cell lung cancer (NSCLC), will also be presented. This first-in-class ADC has shown positive topline results previously.

Additional presentations will include data from the MIRASOL trial of mirvetuximab soravtansine (MIRV) in platinum-resistant ovarian cancer and a pooled analysis of long-term survivors from clinical trials involving patients with folate receptor alpha-positive recurrent ovarian cancer treated with MIRV monotherapy.

AbbVie’s ADCs use innovative mechanisms to target specific protein biomarkers, delivering potent anticancer agents directly to tumors. ABBV-400 and ABBV-706 utilize a topoisomerase 1 inhibitor (Top1i) payload, which interrupts DNA replication to induce cell death. Teliso-V uses a microtubule polymerization inhibitor, monomethyl auristatin E (MMAE).

The company emphasizes its commitment to transforming cancer treatment through targeted therapies. Their pipeline includes more than 20 investigational medicines in clinical trials across various cancer types. AbbVie's goal is to develop innovative solutions that address challenging cancers, enhancing patient outcomes and access to their therapies.